You are here

Publications

Search

Show only items where

Author

Type

Term

Year

Keyword

Found 1654 results

Filters: First Letter Of Last Name is B [Clear All Filters]

2022

Smith, C. R., Aranda, R., Bobinski, T. P., Briere, D. M., Burns, A. C., Christensen, J. G., Clarine, J., Engstrom, L. D., Gunn, R. J., Ivetac, A., Jean-Baptiste, R., Ketcham, J. M., Kobayashi, M., Kuehler, J., Kulyk, S., J Lawson, D., Moya, K., Olson, P., Rahbaek, L., Thomas, N. C., Wang, X., Waters, L. M., and Marx, M. A. (2022) Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of -Deleted Cancers.. J Med Chem. 10.1021/acs.jmedchem.1c01900

Smith, C. R., Aranda, R., Bobinski, T. P., Briere, D. M., Burns, A. C., Christensen, J. G., Clarine, J., Engstrom, L. D., Gunn, R. J., Ivetac, A., Jean-Baptiste, R., Ketcham, J. M., Kobayashi, M., Kuehler, J., Kulyk, S., J Lawson, D., Moya, K., Olson, P., Rahbaek, L., Thomas, N. C., Wang, X., Waters, L. M., and Marx, M. A. (2022) Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of -Deleted Cancers.. J Med Chem. 10.1021/acs.jmedchem.1c01900

Smith, C. R., Aranda, R., Bobinski, T. P., Briere, D. M., Burns, A. C., Christensen, J. G., Clarine, J., Engstrom, L. D., Gunn, R. J., Ivetac, A., Jean-Baptiste, R., Ketcham, J. M., Kobayashi, M., Kuehler, J., Kulyk, S., J Lawson, D., Moya, K., Olson, P., Rahbaek, L., Thomas, N. C., Wang, X., Waters, L. M., and Marx, M. A. (2022) Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of -Deleted Cancers.. J Med Chem. 10.1021/acs.jmedchem.1c01900

Liu, L., Wilcox, X. E., Fisher, A. J., Boyd, S. D., Zhi, J., Winkler, D. D., and Bulla, L. A. (2022) Functional and Structural Analysis of the Toxin-Binding Site of the Cadherin G-Protein-Coupled Receptor, BT-R, for Cry1A Toxins of . Biochemistry. 61, 752-766

Liu, L., Wilcox, X. E., Fisher, A. J., Boyd, S. D., Zhi, J., Winkler, D. D., and Bulla, L. A. (2022) Functional and Structural Analysis of the Toxin-Binding Site of the Cadherin G-Protein-Coupled Receptor, BT-R, for Cry1A Toxins of . Biochemistry. 61, 752-766

Moghadasi, S. Arad, Esler, M. A., Otsuka, Y., Becker, J. T., Moraes, S. N., Anderson, C. B., Chamakuri, S., Belica, C., Wick, C., Harki, D. A., Young, D. W., Scampavia, L., Spicer, T. P., Shi, K., Aihara, H., Brown, W. L., and Harris, R. S. (2022) Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M/3CL in Living Cells. mBio. 10.1128/mbio.00784-22

Moghadasi, S. Arad, Esler, M. A., Otsuka, Y., Becker, J. T., Moraes, S. N., Anderson, C. B., Chamakuri, S., Belica, C., Wick, C., Harki, D. A., Young, D. W., Scampavia, L., Spicer, T. P., Shi, K., Aihara, H., Brown, W. L., and Harris, R. S. (2022) Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M/3CL in Living Cells. mBio. 10.1128/mbio.00784-22

Moghadasi, S. Arad, Esler, M. A., Otsuka, Y., Becker, J. T., Moraes, S. N., Anderson, C. B., Chamakuri, S., Belica, C., Wick, C., Harki, D. A., Young, D. W., Scampavia, L., Spicer, T. P., Shi, K., Aihara, H., Brown, W. L., and Harris, R. S. (2022) Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M/3CL in Living Cells. mBio. 10.1128/mbio.00784-22

Wicky, B. I. M., Milles, L. F., Courbet, A., Ragotte, R. J., Dauparas, J., Kinfu, E., Tipps, S., Kibler, R. D., Baek, M., DiMaio, F., Li, X., Carter, L., Kang, A., Nguyen, H., Bera, A. K., and Baker, D. (2022) Hallucinating symmetric protein assemblies. Science. 378, 56-61

Wicky, B. I. M., Milles, L. F., Courbet, A., Ragotte, R. J., Dauparas, J., Kinfu, E., Tipps, S., Kibler, R. D., Baek, M., DiMaio, F., Li, X., Carter, L., Kang, A., Nguyen, H., Bera, A. K., and Baker, D. (2022) Hallucinating symmetric protein assemblies. Science. 378, 56-61

Wicky, B. I. M., Milles, L. F., Courbet, A., Ragotte, R. J., Dauparas, J., Kinfu, E., Tipps, S., Kibler, R. D., Baek, M., DiMaio, F., Li, X., Carter, L., Kang, A., Nguyen, H., Bera, A. K., and Baker, D. (2022) Hallucinating symmetric protein assemblies. Science. 378, 56-61

Gnann, A. D., Xia, Y., Soule, J., Barthélemy, C., Mawani, J. S., Musoke, S. Nzikoba, Castellano, B. M., Brignole, E. J., Frueh, D. P., and Dowling, D. P. (2022) High-resolution structures of a siderophore-producing cyclization domain from Yersinia pestis offer a refined proposal of substrate binding. J Biol Chem. 298, 102454

Gnann, A. D., Xia, Y., Soule, J., Barthélemy, C., Mawani, J. S., Musoke, S. Nzikoba, Castellano, B. M., Brignole, E. J., Frueh, D. P., and Dowling, D. P. (2022) High-resolution structures of a siderophore-producing cyclization domain from Yersinia pestis offer a refined proposal of substrate binding. J Biol Chem. 298, 102454

Hickerson, B. T., Daniels-Wells, T. R., Payes, C., Clark, L. E., Candelaria, P. V., Bailey, K. W., Sefing, E. J., Zink, S., Ziegenbein, J., Abraham, J., Helguera, G., Penichet, M. L., and Gowen, B. B. (2022) Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections. Nat Commun. 13, 558

Goodman, K. Marie, Katsamba, P. S., Rubinstein, R., Ahlsen, G., Bahna, F., Mannepalli, S., Dan, H., Sampogna, R. V., Shapiro, L., and Honig, B. (2022) How clustered protocadherin binding specificity is tuned for neuronal self-/nonself-recognition. Elife. 10.7554/eLife.72416

Bubenik, M., Mader, P., Mochirian, P., Vallée, F., Clark, J., Truchon, J. - F., Perryman, A. L., Pau, V., Kurinov, I., Zahn, K. E., Leclaire, M. - E., Papp, R., Mathieu, M. - C., Hamel, M., Duffy, N. M., Godbout, C., Casas-Selves, M., Falgueyret, J. - P., Baruah, P. S., Nicolas, O., Stocco, R., Poirier, H., Martino, G., Fortin, A. Bonneau, Roulston, A., Chefson, A., Dorich, S., St-Onge, M., Patel, P., Pellerin, C., Ciblat, S., Pinter, T., Barabé, F., Bakkouri, M. El, Parikh, P., Gervais, C., Sfeir, A., Mamane, Y., Morris, S. J., W Black, C., Sicheri, F., and Gallant, M. (2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998

Bubenik, M., Mader, P., Mochirian, P., Vallée, F., Clark, J., Truchon, J. - F., Perryman, A. L., Pau, V., Kurinov, I., Zahn, K. E., Leclaire, M. - E., Papp, R., Mathieu, M. - C., Hamel, M., Duffy, N. M., Godbout, C., Casas-Selves, M., Falgueyret, J. - P., Baruah, P. S., Nicolas, O., Stocco, R., Poirier, H., Martino, G., Fortin, A. Bonneau, Roulston, A., Chefson, A., Dorich, S., St-Onge, M., Patel, P., Pellerin, C., Ciblat, S., Pinter, T., Barabé, F., Bakkouri, M. El, Parikh, P., Gervais, C., Sfeir, A., Mamane, Y., Morris, S. J., W Black, C., Sicheri, F., and Gallant, M. (2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998

Bubenik, M., Mader, P., Mochirian, P., Vallée, F., Clark, J., Truchon, J. - F., Perryman, A. L., Pau, V., Kurinov, I., Zahn, K. E., Leclaire, M. - E., Papp, R., Mathieu, M. - C., Hamel, M., Duffy, N. M., Godbout, C., Casas-Selves, M., Falgueyret, J. - P., Baruah, P. S., Nicolas, O., Stocco, R., Poirier, H., Martino, G., Fortin, A. Bonneau, Roulston, A., Chefson, A., Dorich, S., St-Onge, M., Patel, P., Pellerin, C., Ciblat, S., Pinter, T., Barabé, F., Bakkouri, M. El, Parikh, P., Gervais, C., Sfeir, A., Mamane, Y., Morris, S. J., W Black, C., Sicheri, F., and Gallant, M. (2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998

Bubenik, M., Mader, P., Mochirian, P., Vallée, F., Clark, J., Truchon, J. - F., Perryman, A. L., Pau, V., Kurinov, I., Zahn, K. E., Leclaire, M. - E., Papp, R., Mathieu, M. - C., Hamel, M., Duffy, N. M., Godbout, C., Casas-Selves, M., Falgueyret, J. - P., Baruah, P. S., Nicolas, O., Stocco, R., Poirier, H., Martino, G., Fortin, A. Bonneau, Roulston, A., Chefson, A., Dorich, S., St-Onge, M., Patel, P., Pellerin, C., Ciblat, S., Pinter, T., Barabé, F., Bakkouri, M. El, Parikh, P., Gervais, C., Sfeir, A., Mamane, Y., Morris, S. J., W Black, C., Sicheri, F., and Gallant, M. (2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998

Bubenik, M., Mader, P., Mochirian, P., Vallée, F., Clark, J., Truchon, J. - F., Perryman, A. L., Pau, V., Kurinov, I., Zahn, K. E., Leclaire, M. - E., Papp, R., Mathieu, M. - C., Hamel, M., Duffy, N. M., Godbout, C., Casas-Selves, M., Falgueyret, J. - P., Baruah, P. S., Nicolas, O., Stocco, R., Poirier, H., Martino, G., Fortin, A. Bonneau, Roulston, A., Chefson, A., Dorich, S., St-Onge, M., Patel, P., Pellerin, C., Ciblat, S., Pinter, T., Barabé, F., Bakkouri, M. El, Parikh, P., Gervais, C., Sfeir, A., Mamane, Y., Morris, S. J., W Black, C., Sicheri, F., and Gallant, M. (2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998

Chandran, S. S., Ma, J., Klatt, M. G., Dündar, F., Bandlamudi, C., Razavi, P., Wen, H. Y., Weigelt, B., Zumbo, P., Fu, S. Ning, Banks, L. B., Yi, F., Vercher, E., Etxeberria, I., Bestman, W. D., Paula, A. Da Cruz, Aricescu, I. S., Drilon, A., Betel, D., Scheinberg, D. A., Baker, B. M., and Klebanoff, C. A. (2022) Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 28, 946-957

Chandran, S. S., Ma, J., Klatt, M. G., Dündar, F., Bandlamudi, C., Razavi, P., Wen, H. Y., Weigelt, B., Zumbo, P., Fu, S. Ning, Banks, L. B., Yi, F., Vercher, E., Etxeberria, I., Bestman, W. D., Paula, A. Da Cruz, Aricescu, I. S., Drilon, A., Betel, D., Scheinberg, D. A., Baker, B. M., and Klebanoff, C. A. (2022) Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 28, 946-957

Chandran, S. S., Ma, J., Klatt, M. G., Dündar, F., Bandlamudi, C., Razavi, P., Wen, H. Y., Weigelt, B., Zumbo, P., Fu, S. Ning, Banks, L. B., Yi, F., Vercher, E., Etxeberria, I., Bestman, W. D., Paula, A. Da Cruz, Aricescu, I. S., Drilon, A., Betel, D., Scheinberg, D. A., Baker, B. M., and Klebanoff, C. A. (2022) Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 28, 946-957

Chandran, S. S., Ma, J., Klatt, M. G., Dündar, F., Bandlamudi, C., Razavi, P., Wen, H. Y., Weigelt, B., Zumbo, P., Fu, S. Ning, Banks, L. B., Yi, F., Vercher, E., Etxeberria, I., Bestman, W. D., Paula, A. Da Cruz, Aricescu, I. S., Drilon, A., Betel, D., Scheinberg, D. A., Baker, B. M., and Klebanoff, C. A. (2022) Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 28, 946-957

Chandran, S. S., Ma, J., Klatt, M. G., Dündar, F., Bandlamudi, C., Razavi, P., Wen, H. Y., Weigelt, B., Zumbo, P., Fu, S. Ning, Banks, L. B., Yi, F., Vercher, E., Etxeberria, I., Bestman, W. D., Paula, A. Da Cruz, Aricescu, I. S., Drilon, A., Betel, D., Scheinberg, D. A., Baker, B. M., and Klebanoff, C. A. (2022) Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 28, 946-957

Pages

Quick Links

The Northeastern Collaborative Access Team (NE-CAT) facility at the Advanced Photon Source at Argonne National Laboratory is managed by Cornell University and consists of eight member institutions:

Columbia University
Cornell University
Genentech
Harvard University
Memorial Sloan-Kettering Cancer Center
Massachusetts Institute of Technology
Rockefeller University
Yale University

Primary funding for this project comes from the National Institute of General Medical Sciences (NIGMS), a division of the National Institutes of Health (NIH). Additional financial support for NE-CAT comes from the member institutions.